Abstract: Methods of modulating IL-10 signaling in a diabetic patient are provided. The methods include administering a therapeutically effective amount of an agent that inhibits Interleukin-10 (IL-10) signaling to a wound site. The agent may antagonize IL-10 or IL-10R to inhibit IL-10 signaling. In some aspects the agent is an antibody or antigen-binding fragment that specifically binds to IL-10 or IL-10R.

Abstract: The present disclosure is directed to methods of utilizing echocardiography for assessing hemodynamic significance of patent ductus arteriosus (PDA) at early time points to supplement a patient's clinical and laboratory data by determining a PDA severity score. The present disclosure is further directed to treating the patient for PDA based on the severity score.

Abstract: Methods for treating viral respiratory syndromes are disclosed. In some aspects, the methods include administering a non-sedative therapeutically effective amount of an ?-2 adrenergic receptor (AR) agonist to the subject. In some aspects, the methods include administering a therapeutically effective amount of an ?-2 adrenergic receptor (AR) agonist and a therapeutically effective amount of an ?-1 adrenergic receptor (AR) antagonist to the subject.

Abstract: The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-? protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor ? (“PPAR?”) to a human or veterinary subject in need of such treatment.

Abstract: This disclosure provides for automatic oxygen titration in high flow and low flow oxygen therapy based on targeted oxygen saturation levels. For example, this disclosure involves an algorithm that can automatically titrate and adjust oxygen fraction (FiO2) of an oxygen therapy medical device based on the peripheral capillary oxygen saturation (SpO2) of the patient to achieve a targeted SpO2. This can allow for continuously monitoring and recording of delivered FiO2 and SpO2. In addition, the administered FiO2 can be adjusted according to patient SpO2 and target SpO2 goals. The disclosure can be adapted to any high flow oxygen device and any low flow oxygen device, such as a flowmeter. In addition, clinicians or other users can be alerted about changes in a subject's oxygenation status with an alarm function.

Abstract: The present invention generally relates to a positioning device for positioning the limbs of a patient placed on an operating room table and to methods of using such a device. In one embodiment, the device provides for the positioning of the arms of a patient positioned supine on an operating room table.

Abstract: An aspect of the present disclosure describes a system for providing continuous and progressive auditory feedback based on real-time orthopedic sensor data, which includes a plurality of plantar pressure sensors, an audio output device, and a mobile device. The mobile device receives receive, from at least one of the plantar pressure sensors, one or more sensor values indicative of an actual movement of a user during a training session. The mobile device determines, based on an evaluation of the sensor values, a similarity of the actual movement to a target movement. The mobile device modifies, as a function of the similarity of the actual movement to the target movement, an auditory feedback, and causes the audio output device to output the auditory feedback.

Abstract: Methods of treating triple negative breast cancer (TNBC) using antibodies against p40 monomer are described herein. In some aspects, methods of treatment for TNBC include administration of antibodies against p40 monomer or administration of antibodies against p40 monomer in combination with a binding peptide such as TLR2-interacting domain of MyD88 (TIDM) peptide or NEMO-binding domain (NBD) peptide. Methods of treating other cancers using antibodies against p40 monomer in combination with a binding peptide such as TIDM peptide or NBD peptide are described herein.

Abstract: Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

Abstract: A method for monitoring a treatment of a subject having a musculoskeletal disorder is provided. The method includes measuring a first expression level of at least two biomarkers at a treatment site prior to the treatment and measuring a second expression level of the at least two biomarkers at the treatment site after the treatment begins. The method further includes comparing the first expression level of the at least two biomarkers prior to the treatment to the second expression level of the at least two biomarkers post treatment and continuing the treatment, altering the treatment or stopping the treatment based on the comparison. A method of treating a musculoskeletal disorder in a subject is also provided. The method includes removing a aggrecan-hyaluronan matrix from a treatment site in the subject.

Abstract: Predictions can be provided for admission, discharge, pathway, and units for a patient during a stay at a healthcare facility. In some aspects, a computing device receives initial data regarding the patient and generates an admission or discharge prediction indicating a probability that the patient will be admitted to or discharged from the healthcare facility. The computing device segments portions of the initial data into segmented data and stores the segmented data in one or more of a plurality of segmentation categories. The computing device compares the segmented data to one or more patterns of a predictive model and, based on the comparing, generates a total length-of-stay (LOS) prediction indicating a duration of time for which the patient will stay at the healthcare facility.

Abstract: The disclosure is directed to an apparatus and a method for improving manual ventilation and resuscitation by monitoring ventilation parameters and assisting resuscitation. The apparatus includes a gas flow sensor configured to measure a flow rate of exhaled gas of a subject. The apparatus is configured to receive an ideal body weight or a predicated body weight of the subject and calculate a first tidal volume range based on the ideal body weight or the predicated body weight of the subject. The apparatus is also configured to obtain an exhaled tidal volume of the subject based on the measured flow rate and determine whether the exhaled tidal volume is within the first tidal volume range. When it is determined that the exhaled tidal volume is not within the first tidal volume range, the apparatus is further configured to perform a first tidal volume warning.

Abstract: Various aspects of the present invention provide an apparatus and a method of removing an orthopedic implant from a patient. In one embodiment, the method includes cycling the temperature of at least a portion of the orthopedic implant between a first temperature and a second temperature that differs from the first temperature. In one embodiment, the first temperature is above 0° C. and the second temperature is below 0° C. The temperature cycling causes a thermal expansion differential between at least a portion of the orthopedic implant and material in a region contacting the orthopedic implant. In one embodiment, the thermal expansion differential is of an extent sufficient to cause physical separation of at least a portion of the surface of the orthopedic implant from material contacting the surface of the orthopedic implant.

Abstract: One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

Abstract: Certain aspects of the invention provide a system and a method for treating an epileptic condition or a tumor of the brain. In one embodiment, the method of treating the epileptic condition includes acquiring inter- and post-ictal imaging profiles and from the brain of the patient and determining an ictal propagation pathway based on the profiles. A volume of cortical activation is determined for each of a plurality of virtual electrode placement positions based on the ictal propagation pathway and the virtual electrode placement position. An electrode is implanted at a position selected from the plurality of virtual electrode placement positions, based on the volume of cortical activation at the implantation position. An electrical pulse is delivered from the electrode, where the electrical pulse is of a magnitude and duration effective to at least reduce the epileptic seizure.

Abstract: Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.

Abstract: The present invention generally relates to compositions and methods for treating a neurological disorder in a subject, the method including administering to the subject in need of such treatment a composition including a therapeutically effective amount of a CCR5 antagonist. The CCR5 antagonist may be, for example, maraviroc. The neurological disorder may be, for example, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies or multiple system atrophy.

Abstract: Methods of modulating peroxisome proliterator-activated receptor ? (PPAR?) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAP? ligand to the subject where the PPAP? ligand is selected from 1,3-Di-tertbutyl benzene (DBB), 2,4-Di-tertbutyl phenol (DBP), Methyl palmitate (MePA), 2,6-Di-tertbutyl-4-Methyl Phenol (DBMP), 3,4-Di-tertbutyl-Phenol (3,4-DBP), 2,3-Di-tertbutyl-Phenol (2,3-DBP), and 2,6-Di-tertbutyl-Phenol (2,6-DBP).

Abstract: Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.

Abstract: Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1?, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1?, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof.